Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 11;13(1):31.
doi: 10.1186/s40035-024-00421-0.

DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease

Ellen Appleton #  1 , Shervin Khosousi #  1 , Michael Ta  2   3   4 , Michael Nalls  2   3   4 , Andrew B Singleton  2   4 , Andrea Sturchio  1   5 , Ioanna Markaki  1 , Wojciech Paslawski  1 , Hirotaka Iwaki  2   3   4 , Per Svenningsson  6   7
Affiliations

DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease

Ellen Appleton et al. Transl Neurodegener. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

H.I. and M.A.N.’s participation in this project was part of a competitive contract awarded to Data Tecnica LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board at Clover Therapeutics and is an advisor and scientific founder at Neuron23 Inc. A.S cofounded REGAIN Therapeutics and is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” All other authors report no conflicts of interest.

Figures

Fig. 1
Fig. 1
CSF and plasma DDC levels in prodromal, de novo and treated PD. a–d Volcano plots showing differential abundance of 1463 proteins in the CSF, corrected for age and sex. Axes display Log2 fold change and Benjamini–Hochberg adjusted P-values. Plots show PD (n = 84) versus controls (n = 54) in the PDBP cohort (a), prodromal PD (n = 51) versus controls (n = 130) (b) and de novo PD (n = 74) versus controls (n = 130) (c) in the PPMI cohort, and PD (n = 120) versus controls (n = 69) (66 proteins) in the Biopark cohort (d). e–g Box-plots of age- and sex-adjusted CSF DDC levels in PD and controls from the PDBP cohort (independent t-test) (e), prodromal, de novo PD and control samples from the PPMI cohort (ANOVA, Tukey post-hoc test) (f), and de novo PD, PD and control samples from the Biopark cohort (ANOVA, Tukey post-hoc test) (g). h Receiver operating characteristic (ROC) curves for CSF DDC levels with area under the curve (AUC) for prodromal or PD vs controls in each cohort. i–l Volcano plots showing differential abundance of 1463 proteins in plasma, corrected for age and sex. Axes display Log2 fold change and Benjamini–Hochberg adjusted P-values. Plots show PD (n = 84) versus controls (n = 54) in the PDBP cohort (i), prodromal PD (n = 62) versus controls (n = 130) (j) and de novo PD (n = 78) versus controls (n = 130) (k) in the PPMI cohort, and PD (n = 238) versus controls (n = 50) (71 proteins) in the Biopark cohort (l). m–o Box-plots of age- and sex-adjusted plasma DDC levels in PD and controls from the PDBP cohort (independent t-test) (m), prodromal, de novo PD and control samples from the PPMI cohort (ANOVA, Tukey post-hoc test) (n), and de novo PD, PD and control samples from the Biopark cohort (ANOVA, Tukey post-hoc test) (o). p ROC curves for plasma DDC levels with AUC for prodromal or PD vs controls in each cohort. *P < 0.05, ****P < 0.0001
See this image and copyright information in PMC

References

    1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–2303. doi: 10.1016/S0140-6736(21)00218-X. - DOI - PubMed
    1. Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–417. doi: 10.1016/S1474-4422(23)00109-6. - DOI - PMC - PubMed
    1. Paslawski W, Khosousi S, Hertz E, Markaki I, Boxer A, Svenningsson P. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease. Transl Neurodegener. 2023;12(1):42. doi: 10.1186/s40035-023-00374-w. - DOI - PMC - PubMed
    1. Pereira JB, Kumar A, Hall S, Palmqvist S, Stomrud E, Bali D, et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat Aging. 2023;3(10):1201–1209. doi: 10.1038/s43587-023-00478-y. - DOI - PMC - PubMed
    1. Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok AHYS, Lleó A, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer’s disease. Nat Commun. 2023;14(1):5635. doi: 10.1038/s41467-023-41122-y. - DOI - PMC - PubMed

Publication types